Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›

Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›

Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging. Read More ›

Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›

Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY^® (piflufolastat F 18). Read More ›